A Phase I Study to Investigate the PK, Safety and Tolerability of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

Study identifier:D6402C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase I, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability Following Administration of a Single Dose of Balcinrenone/Dapagliflozin in Healthy Chinese Participants

Medical condition

Healthy Volunteer

Phase

Phase 1

Healthy volunteers

Yes

Study drug

balcinrenone/dapagliflozin

Sex

All

Estimated Enrollment

10

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 03 Dec 2024
Estimated Primary Completion Date: 03 Apr 2025
Estimated Study Completion Date: 03 Apr 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria